Oncostatin M is produced during pregnancy by decidual cells and stimulates the release of HCG.
Oncostatin M (OSM) is a member of the interleukin-6 superfamily and a multifunctional cytokine that effects the growth and differentiation of many different cell types. OSM concentrations in the sera of pregnant women were found to be significantly higher than those of non-pregnant women. Western blot analysis revealed that the OSM protein was present in the decidua and chorionic tissue in each trimester. Throughout pregnancy, the amount of the OSM protein in the decidua was larger than that in the chorionic tissue. Immunohistochemistry using an anti-OSM monoclonal antibody demonstrated that OSM was mainly localized in the decidual glands and stroma. OSM transcripts in the decidua and the chorionic tissue were detected during each trimester by reverse transcription-polymerase chain reaction (RT-PCR). The regulation of human chorionic gonadotrophin (HCG) release by the placenta in first trimester stimulated with recombinant OSM was also investigated. Stimulation of the placenta by OSM augmented HCG release in a time- and dose-dependent manner. HCG release induced by recombinant human OSM was completely blocked by antibodies against OSM and the signal transducer, gp130, but only partially inhibited by antibodies against the leukaemia inhibiting factor (LIF) receptor. These results suggest that OSM molecules produced by decidual glands and stromal cells during pregnancy have an important role in placental endocrine function.
Ogata
I
I
Department of Obstetrics and Gynecology, Faculty of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan.
Shimoya
K
K
Moriyama
A
A
Shiki
Y
Y
Matsumura
Y
Y
Yamanaka
K
K
Nobunaga
T
T
Tokugawa
Y
Y
Kimura
T
T
Koyama
M
M
Azuma
C
C
Murata
Y
Y
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000276:immunology; D002823:Chorion / Q000187:drug effects / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D050822:Cytokine Receptor gp130; D003656:Decidua / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006131:Growth Inhibitors; D006801:Humans; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008222:Lymphokines; D008562:Membrane Glycoproteins / Q000276:immunology; D053683:Oncostatin M; D010455:Peptides / Q000494:pharmacology / Q000502:physiology*; D011247:Pregnancy / Q000378:metabolism*; D011264:Pregnancy Trimesters; D018121:Receptors, Cytokine / Q000276:immunology; D053606:Receptors, OSM-LIF
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D006063:Chorionic Gonadotropin; D006131:Growth Inhibitors; C494199:IL6ST protein, human; D015850:Interleukin-6; C507837:LIF protein, human; C507840:LIFR protein, human; D053605:Leukemia Inhibitory Factor; D053680:Leukemia Inhibitory Factor Receptor alpha Subunit; D008222:Lymphokines; D008562:Membrane Glycoproteins; C508351:OSM protein, human; D010455:Peptides; D018121:Receptors, Cytokine; D053606:Receptors, OSM-LIF; D053683:Oncostatin M; D050822:Cytokine Receptor gp130